ILOPROST - Community register of orphan medicinal products

Vous trouverez des articles traitant du même sujet dans la catégorie "HTAP"

Problèmes que peuvent renconter les patients atteints de la maladie de Gaucher

Liens utiles à la fin des catégories.

Ghislaine SURREL

maladies-lysosomales-subscribe@yahoogroupes

Pharmaceuticals > Register > Orphan medicinal products > Iloprost

Last update: 21 April 2005 

Iloprost 

EU orphan designation number:
	EU/3/00/014
Active ingredient:
	Iloprost
Indication:
	Treatment of primary and of the following forms of secondary pulmonary hypertension: connective tissue disease pulmonary hypertension, drug-induced pulmonary hypertension, portopulmonary hypertension, pulmonary hypertension associated with congenital heart disease, chronic thromboembolic pulmonary hypertension
Sponsor:
	Schering AG
EU Centralised marketing authorisation:
	A centralised EU marketing authorisation has been obtained under the name Ventavis on 16/09/2003 with the number EU/1/03/255/...

European Commission procedures 

Close date procedure	Procedure type	EMEA number	Decision
29/12/2000	Orphan - Initial designation	-	C(2000)4251 of 29/12/2000